Abstract
Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/ organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
Keywords: Systemic Sclerosis, fibrosis, biologic therapies, Rituximab, Tocilizumab.
Current Medicinal Chemistry
Title:Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Volume: 22 Issue: 16
Author(s): Theodoros Dimitroulas, Dimitrios Daoussis, Alexandros Garyfallos, Petros P. Sfikakis and George D. Kitas
Affiliation:
Keywords: Systemic Sclerosis, fibrosis, biologic therapies, Rituximab, Tocilizumab.
Abstract: Recent advances have shed light on the complex pathogenic processes that underlie the development and progression of Systemic Sclerosis (SSc) but management of the disease remains problematic and curative treatment is not available. Better understanding of the underlying pathology has enabled novel therapeutic approaches to be investigated, as therapies in rheumatology are becoming increasingly disease/ organ-specific, targeting unique biological networks and signalling pathways. The pathophysiologic and clinical pleiomorphism of SSc however, represents a major barrier to conducting large well-controlled studies for the evaluation of non-selective immunosuppressive and novel highly selective agents. Therapeutic biologic strategies targeting inflammatory or profibrotic cytokines and lymphocyte activation proved to be efficacious in other systemic rheumatic diseases but have demonstrated contradictory results in SSc. Blocking of tumour necrosis factor alpha and interleukin-6 may improve SSc-associated arthritis, while depletion of B-cells may have benefits for skin and lung fibrosis, but randomized studies are needed. In this review we critically appraise available data for the treatment of SSc focusing on immunologic and antifibrotic strategies. Attenuation of the fibrotic process remains an unmet goal but the potential to prevent damage by promoting tissue repair has been shown in preclinical studies. Translation of these findings into clinical practice will hopefully establish new therapeutic options and improve prognosis of these patients, for which our therapeutic armamentarium remains poor.
Export Options
About this article
Cite this article as:
Dimitroulas Theodoros, Daoussis Dimitrios, Garyfallos Alexandros, P. Sfikakis Petros and D. Kitas George, Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150209161224
DOI https://dx.doi.org/10.2174/0929867322666150209161224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications
Current Radiopharmaceuticals Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology Colchicine in Renal Diseases: Present and Future
Current Pharmaceutical Design The Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia
Current Cardiology Reviews Heart Failure in South America
Current Cardiology Reviews Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare
Current Medicinal Chemistry Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update
Current Respiratory Medicine Reviews Dietary Modulation of Thymic Enzymes
Endocrine, Metabolic & Immune Disorders - Drug Targets History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in Metabolic and Related Cardiovascular Diseases
Current Molecular Pharmacology Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued)